Our clinical strategy harnesses the unique capabilities of
oncolytic viruses for effective cancer treatment
Our goal is to deliver clinical benefits to patients, such as halting the progression of cancer and enhancing survival rates. In addition to continuous innovation of our OV backbone, Virogin is reimagining and redesigning clinical trial strategies, pushing the envelope to fully unleash the potential of oncolytic virotherapy.
• Targeting the highest unmet medical needs
• Enrichment of potential responders based on biomarkers to achieve significantly prolonged OS (overall survival) of late-stage cancer patients
• Expertise in navigating the regulatory pathway for accelerated approvals
• Global clinical data sharing for approvals of multiple regions
• Systemic and local treatment: intravenous and intra-tumoral
Our Regulatory Milestones
VG201: Intravenous (IV) administration was approved by NMPA
VG201: First patient dosed for combination arm with Nivolumab
VG203: Received CDE IND approval
VG161: Combination arm with Nivolumab approved by FDA
VG203: Received FDA IND approval
VG201: Phase I clinical trials have been initiated in China & US
